Amanta Healthcare Share Price Target 2025, 2026, 2030, 2040, 2050
Amanta Healthcare is an Indian company, started in 1994 and makes medicines and medical devices. It mainly makes sterile liquid products like IV fluids, eye drops, breathing support medicines, and cleaning solutions used in hospitals. The company also makes some medical devices. To keep the products safe and clean, it uses modern technology for packaging. It has well-equipped factories in Kheda (Gujarat) and Goa. The company sells more than 45 types of medicines across India through distributors and also sends its products to countries in Africa, Latin America, and Europe.
- 1 What is Amanta Healthcare Ltd NSE: AMANTA?
- 2 Amanta Healthcare Share Price
- 3 Amanta Healthcare Share Price Target 2025
- 4 Amanta Healthcare share price Target 2026
- 5 Share price Target 2027
- 6 Share price Target 2028
- 7 Share price Target 2029
- 8 Amanta Healthcare share price Target 2030
- 9 Share price Target 2040
- 10 Share Price Target 2050
- 11 Should I buy Amanta Healthcare stock?
- 12 Amanta Healthcare earnings results (Financials)
- 13 Is Amanta Healthcare stock good to buy? (bull case & bear case)
- 14 Bear Case:
- 15 Conclusion
- 16 FAQs
What is Amanta Healthcare Ltd NSE: AMANTA?
Amanta Healthcare, established in 1994 in Gujarat. It is owned by the Patel family and was formerly known as Marck Biosciences. It is a pharmaceutical company that mainly makes liquid medicines such as injections, eye drops, respiratory products, and fluids used in hospitals. The company has factories in Kheda and Goa, where it uses advanced and hygienic technology like Blow-Fill-Seal (BFS) to make sure the medicines are safe and free from germs. In India, it supplies medicines through over 320 distributors and also exports to more than 21 countries across Africa, Latin America, and Europe.
It makes over 45 generic medicines, which are sold under its own brand names across India through a large network of more than 320 distributors and stockists. It also exports its products to many countries, including Africa, Latin America, and the UK. In the financial year 2025, its products were approved in 19 countries and sold in 21, showing that the company is growing internationally. It creates new products, follows different countries’ rules, and reaches more markets around the world by partnering with other companies. In 2025, its share price target would be ₹274, as per stock market analysts.
According to stock market analysts, its share price would be between ₹88 to ₹274 in 2025
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2025 | 88 | 274 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| September | 100 | 174 |
| October | 88 | 188 |
| November | 125 | 214 |
| December | 184 | 274 |
It did well financially even though its sales went down a little. The company made much more profit, it controlled costs and expenses and worked more efficiently. It also borrowed less money and became stronger financially. It kept steady profits and made good returns on the money it used in the business. In the future, the company plans to grow by adding two new production setups at its factory in Hariyala, Gujarat, one to make sterile products and another for small injections. In 2026, its share price target would be ₹450, as per stock market analysts.
Its share price would be between ₹220 to ₹450 in 2026, as per stock market analysts
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2026 | 220 | 450 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 220 | 270 |
| February | 228 | 289 |
| March | 234 | 298 |
| April | 224 | 300 |
| May | 237 | 321 |
| June | 240 | 332 |
| July | 247 | 340 |
| August | 250 | 347 |
| September | 262 | 360 |
| October | 260 | 378 |
| November | 288 | 400 |
| December | 300 | 450 |
The company makes many safe and trusted medical products that doctors use all over the world. These include medicines for breathing problems, eye care, fluids to help patients stay hydrated, medicines to fight infections, liquids to mix medicines, ready-to-use injections, and reliable sets for giving fluids through IV. It focuses on new ideas and technology to make better and safer healthcare products, like special containers for IV fluids and improved tools for IV treatment. The company has a strong system to sell and deliver its products in India and other countries, making sure they get to patients on time. In 2027, its share price target would be ₹627, as per stock market analysts.
According to stock market analysts, its share price would be between ₹380 to ₹627 in 2027.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2027 | 380 | 627 |
It knows that the medicine industry is always changing. It started by making large IV fluids and now makes many different sterile products like irrigation solutions, medicines for eyes and breathing, and small injections. As it is a medium-sized company, it has big goals and many top medicine companies trust it to help from the first idea to the final product. It focuses on learning, research, and flexible making of products, allowing it to make everything from small injections to large irrigation fluids, making it a strong and creative partner in healthcare. In 2028, its share price target would be ₹838, as per stock market analysts.
According to stock market analysts, its share price would be between ₹602 to ₹838 in 2028.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2028 | 602 | 838 |
It makes many types of sterile liquid medicines using modern technology, and sells them both in India and other countries. Their large-volume products include common fluids, electrolyte replacements, antibiotics, medicines to help with urination, and medicines to fight infections and fungi. Their small-volume products include liquids used in eye care medicines, breathing treatments, and irrigation fluids. Their products include breathing treatments for lung problems, eye drops and washes, fluids to keep patients hydrated, medicines to fight infections, and sterile liquids to mix drugs safely. In 2029, its share price target would be ₹1058, as per stock market analysts.
Its share price would be between ₹810 to ₹1058 in 2029, as per stock market analysts.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2029 | 810 | 1058 |
It has a large, modern factory near Kheda, Ahmedabad, where they make sterile liquid medicines in many sizes, from very small bottles to large ones. They use advanced machines from trusted companies, including special equipment that uses nitrogen gas for delicate medicines. The factory has systems to check the air for dust, automatic machines to pack products and find leaks, and special sterilising methods to keep everything safe. They also have excellent water purification and air control systems, and secure access to keep the factory clean and safe at all times. In 2030, its share price target would be ₹1302, as per stock market analysts.
According to stock market analysts, its share price would be between ₹1030 to ₹1302 in 2030.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2030 | 1030 | 1302 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 1030 | 1114 |
| February | 1041 | 1129 |
| March | 1050 | 1154 |
| April | 1047 | 1162 |
| May | 1052 | 1170 |
| June | 1065 | 1179 |
| July | 1060 | 1192 |
| August | 1078 | 1200 |
| September | 1089 | 1214 |
| October | 1100 | 1235 |
| November | 1124 | 1254 |
| December | 1141 | 1302 |
It cares about the environment and works in a clean and safe way. Its factories in Gujarat and Goa use modern machines to keep the products safe and use less energy and water. The company cleans and reuses water, uses lights that save energy, and throws away waste in the right way. It has an ISO 14001:2004 certificate that shows it follows global rules to protect the environment. It also follows health and safety rules from the WHO and local governments. In 2040, its share price target would be ₹3420, as per stock market analysts.
Its share price would be between ₹3150 to ₹3420 in 2040, as per stock market analysts.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2040 | 3150 | 3420 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 3150 | 3265 |
| February | 3165 | 3285 |
| March | 3160 | 3300 |
| April | 3174 | 3317 |
| May | 3186 | 3332 |
| June | 3200 | 3357 |
| July | 3225 | 3374 |
| August | 3254 | 3390 |
| September | 3274 | 3412 |
| October | 3290 | 3457 |
| November | 3325 | 3478 |
| December | 3358 | 3520 |
It sends its products to more than 77 countries. The company checks its work and suppliers to make sure everything is done the right way. In the future, it plans to use solar power and monitor how much pollution it makes. It also works with other groups to recycle waste in safe and smart ways. It knows that helping the environment is something that should never stop. It is helping to make a better and healthier world for everyone by giving good healthcare and using green ideas. In 2050, its share price target would be ₹7780, as per stock market analysts.
According to stock market analysts, its share price would be between ₹7366 to ₹7780 in 2050.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2050 | 7366 | 7780 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 7366 | 7477 |
| February | 7371 | 7490 |
| March | 7389 | 7511 |
| April | 7410 | 7535 |
| May | 7432 | 7554 |
| June | 7440 | 7569 |
| July | 7458 | 7588 |
| August | 7481 | 7611 |
| September | 7474 | 7638 |
| October | 7525 | 7651 |
| November | 7554 | 7687 |
| December | 7611 | 7780 |
Should I buy Amanta Healthcare stock?
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2025 | 88 | 274 |
| 2026 | 220 | 450 |
| 2027 | 380 | 627 |
| 2028 | 602 | 838 |
| 2029 | 810 | 1058 |
| 2030 | 1030 | 1302 |
| 2040 | 3150 | 3420 |
| 2050 | 7366 | 7780 |
The company makes most of its money by selling in India (55%), sending products to other countries (33%), and doing work for other companies (10%). In the past year, its profit grew a lot to ₹10.5 crore, and it keeps a healthy profit margin of about 22%, but it still has some loans to repay.
Amanta Healthcare earnings results (Financials)
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
| Assets | 381.76 | 352.12 | 374.06 |
| Total Income | 276.09 | 281.61 | 262.70 |
| Profit After Tax | 10.50 | 3.63 | -2.11 |
| EBITDA | 61.05 | 58.76 | 56.31 |
| Net Worth | 96.39 | 66.29 | 62.88 |
| Reserves and Surplus | 67.56 | 39.46 | 36.05 |
| Total Borrowing | 195.00 | 205.23 | 215.66 |
Is Amanta Healthcare stock good to buy? (bull case & bear case)
Bull Case:
- It made a profit of ₹10.5 crore in FY25, which is a 189% increase from the previous year.
- It has a profit margin of 22%, showing strong control over costs.
- The company earns money from different sources 55% from India, 33% from exports, and about 11% from contract manufacturing, reducing risk.
- It has international certifications (like WHO-GMP), allowing it to sell in regulated markets like the UK and Sudan.
- It plans to expand with two new manufacturing lines using about ₹100 crore, which could boost future revenue.
- Its plant is highly efficient, running at over 90% capacity, showing strong demand and productivity.
Bear Case:
- It has only one manufacturing facility in Gujarat, so any issue there could impact its entire business.
- It depends on imported raw materials like plastic granules, which can get expensive if oil prices or the rupee rise.
- Its revenue slightly dropped from ₹281.6 crore in FY24 to ₹276 crore in FY25, raising growth concerns.
Conclusion
It is a growing company that makes liquid medicines used in hospitals and sends them to many countries. It uses modern machines, is earning more money now, and plans to grow by building new factories. The company has some loans to pay. But overall, it is doing well and has a strong demand for its products. It looks like a good company for the future, but people should think about both the good and bad sides before investing.
